Xtl Biopharma Ads (XTLB) 1.04 $XTLB XTL

New Post Public Reply Private Reply Replies (0) Message Board

Sep 22, 2016 at 7:02 AM

Xtl Biopharma Ads (XTLB) 1.04 $XTLB

XTL Biopharmaceuticals Announces the European Patent Office has Issued a Patent for its Lupus Drug hCDR1
PR Newswire - Wed Sep 07, 7:32AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced the European Patent Office (EPO) has granted a patent for the Company's lupus drug candidate, hCDR1. Patent EP1594434 entitled, "Parenteral Formulations of Peptides for the Treatment of Systemic Lupus Erythematosus," claims formulations of hCDR1 and use of these pharmaceutical compositions in the treatment of systemic lupus erythematosus (SLE) that may be validated in the EPO's 27 member countries.
XTLB: 1.04 (+0.02)

XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016
PR Newswire - Tue Sep 06, 7:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced the Company's Chief Financial Officer, David Kestenbaum, will present at Rodman & Renshaw's 18th Annual Global Investment Conference on Monday, September, 12, 2016 at 10:25am in the Kennedy I Room, 4th Floor of the Lotte New York Palace Hotel. The conference, sponsored by H.C. Wainwright & Co., will take place in New York City on September 11 - 13, 2016.
XTLB: 1.04 (+0.02)

XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1
PR Newswire - Thu Aug 11, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has filed a new patent application with the U.S. Patent and Trademark Office to protect doses of hCDR1 lower than 0.5 mg weekly, in the treatment of Systemic Lupus Erythematosus (SLE).
XTLB: 1.04 (+0.02)

Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected $4 Billion Market
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / Lupus - invisible, silent; an autoimmune disease where the body's defenses mistakenly attack its own cells and living with lupus is never ending. Up to 5 million people, mainly women of childbearing age, suffer progression of this disorder because of diagnostic confusion. Most present with fever, malaise and facial skin rash suggesting to internists other unrelated health problems. A capricious disease, lupus strikes in skin, joints, kidney, heart, pancreas, colon, eyes, blood...the list continues and flare-ups are sporadic. If organ damage is severe, lupus can be fatal.
XTLB: 1.04 (+0.02), TEVA: 50.48 (+0.12), GSK: 43.21 (+0.15)

XTL Biopharmaceuticals Reports First Quarter 2016 Financial Results & Provides Clinical and Operational Update
PR Newswire - Wed Jun 01, 7:30AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced financial results for the three months ended March 31, 2016 and provided an update on the development program for its lead drug candidate hCDR1 in the treatment of Systemic Lupus Erythematosus (SLE).
XTLB: 1.04 (+0.02)

XTL Biopharmaceuticals to Present at ChinaBio Partnering Forum 2016 in Suzhou, China on May 19, 2016
PR Newswire - Mon May 16, 10:45AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, announced today the Company's CEO Josh Levine will be presenting at the ChinaBio® Partnering Forum in Suzhou, China on Thursday, May 19, 2016 at 2:00 PM.
XTLB: 1.04 (+0.02)

XTL Biopharmaceuticals' Lupus Drug hCDR1 Granted Patent for Pharmaceutical Composition & Manufacturing Processes
PR Newswire - Wed Feb 10, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that its lead drug candidate hCDR1 has been granted a patent by the Israel Patent Office. The patent, titled "Pharmaceutical Compositions Comprising a Peptide and a Substituted ß Cyclodextrin for use in Treating Systemic Lupus Erythematosus and Processes for their Manufacture," addresses the pharmaceutical composition of hCDR1 and its manufacturing processes. The compound hCDR1 and its formulations have been previously granted patents in numerous key jurisdictions including the U.S., Europe, Israel, Japan, China, India, Russia, Australia and Canada.
XTLB: 1.04 (+0.02)

XTL Biopharmaceuticals Joins Corporate Advisory Council of the Lupus Foundation of America
PR Newswire - Wed Jan 27, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has accepted the Lupus Foundation of America's (LFA) invitation to join the foundation's Corporate Advisory Council (CAC) as of January 2016.
XTLB: 1.04 (+0.02)

XTL Biopharmaceuticals Advances Formulation of its hCDR1 Drug for Clinical Trials in the Treatment of Lupus Through use of Cydex Pharmaceuticals' Captisol®
PR Newswire - Wed Jan 13, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has reached agreement with CyDex Pharmaceuticals Inc. (La Jolla, CA) (CyDex) for the use and supply of Captisol® in the formulation of its lead drug, hCDR1, for the treatment of systemic lupus erythematosus (SLE).
XTL: 64.97 (+0.77), XTLB: 1.04 (+0.02)

XTL Biopharmaceuticals Submits Protocol to Yeda for Advanced Clinical Trial of hCDR1 in the Treatment of Lupus
PR Newswire - Mon Jan 11, 7:30AM CST
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus, today announced that it has submitted the full protocol for its advanced stage clinical trial of hCDR1 for the treatment of systemic lupus erythematosus (SLE) to Yeda Research and Development Company Ltd. (Yeda).
XTL: 64.97 (+0.77), XTLB: 1.04 (+0.02)

Cellect Biomed Announces Key Leadership Changes
GlobeNewswire - Mon Nov 09, 7:30AM CST
Cellect Biomed Ltd. (TASE:CLBD) ("Cellect" or the "Company"

, a developer of innovative technology which enables the functional selection of stem cells, announced additions to its management and professional teams in support of its preparations for the commencement of human clinical trials and its planned dual-listing on a U.S. stock exchange.
XTLB: 1.04 (+0.02), ORPN: 1.83 (+0.04)

XTL Biopharmaceuticals to Present at BIO-Europe 2015 in Munich, Germany on November 3rd, 2015
PR Newswire - Mon Oct 26, 8:15AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, announced today that its Chief Executive Officer, Josh Levine, will be presenting at BIO-Europe 2015, being held at the International Congress Center (ICM) in Munich, Germany.
XTL: 64.97 (+0.77), XTLB: 1.04 (+0.02)

XTL Biopharmaceuticals Announces Agreement With Yeda Research and Development Company Ltd. to Amend License Agreement for Lupus Asset
PR Newswire - Tue Oct 13, 7:45AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, today announced that it has reached agreement with Yeda Research and Development Company Ltd. ("Yeda"

to amend the development milestones in the License Agreement signed between the parties in January 2014 for the development of hCDR1 for the treatment of systemic lupus erythematosus (SLE).
XTL: 64.97 (+0.77), XTLB: 1.04 (+0.02)

XTL Biopharmaceuticals to Present at the Rodman & Renshaw 17th Annual Global Investment Conference on September 10th 2015 at the St. Regis Hotel in NYC
PR Newswire - Thu Sep 03, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that its Chief Executive Officer, Josh Levine, will be presenting at The Rodman & Renshaw 17th Annual Global Investment Conference being held at the St. Regis Hotel in New York.
XTL: 64.97 (+0.77), XTLB: 1.04 (+0.02)

XTL Biopharmaceuticals Reports Second Quarter 2015 Results
PR Newswire - Tue Sep 01, 8:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today provided its financial and operational results for the second quarter and the six months ended June 30, 2015.
XTL: 64.97 (+0.77), XTLB: 1.04 (+0.02), NVS: 81.52 (+0.46)

XTL Biopharmaceuticals Provides First Quarter 2015 Financial Update and Announces Focus of Efforts on its Lupus and Multiple Myeloma Assets
PR Newswire - Mon Jun 01, 7:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced that following an evaluation of the market opportunity for it pipeline products, the Company has decided to focus its efforts and expenditures exclusively on its two core assets: hCDR1 for the treatment of SLE/lupus and rHuEPO for "no-option" multiple myeloma patients. XTL also provided its financial and operational results for the first quarter ended March 31, 2015.
XTL: 64.97 (+0.77), XTLB: 1.04 (+0.02)

Earnings Update: Complementary Research on Tantech Holdings, Sypris Solutions, Swisher Hygiene, XTL Biopharmaceuticals, ADMA Biologics
PR Newswire - Mon May 18, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
SYPR: 0.99 (-0.02), TANH: 2.42 (+0.13), ADMA: 7.08 (-0.04), XTLB: 1.04 (+0.02)

XTL Biopharmaceuticals to Present at IATI Biomed 2015 Conference
PR Newswire - Mon May 11, 10:59AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SRG DocketWatch: Tracking FCC Docs in Real-Time

I'll admit it—sometimes the FCC moves like molasses uphill. But keeping track of what they're up to? That's where the real challenge lies. Summit Ridge Group has tossed a lifeline for anyone who's got skin in the game with their new service, SRG DocketWatch. Why SRG DocketWatch Hits the Mark If you're poking your head into more than a few of those 21,000 FCC...

Seaboard's Q3 Financials: A Mixed Bag for Investors

Eyeing Seaboard's Earnings: What's the Deal? Seaboard Corporation just dropped its earnings report for the third quarter, and boy, it's a doozy. The numbers show a mixed bag—like finding out your favorite team won, but your best player got benched with an injury. On the surface, we've got a rise in net sales, but dig a little deeper, and the cracks start to show. Sales...

Fluence Energy Faces Stock Woes Amid Legal Challenges

A Wild Ride for Fluence Energy Shareholders Damn, if you blinked, you might've missed the plummet of Fluence Energy, Inc. (NASDAQ:FLNC). This kind of nosedive, a brutal 34.63% drop, is the stuff investors fear most. It's like finding a flat tire on the road to profits. But here we are, dissecting the mess that unfolded between November 2025 and September 2026. The meat on...

Tellus Offers Seamless Security with Passkey Sign-In

Tellus Brings a New Era of Convenience Even the most innovative, forward-thinking companies occasionally have to change step to keep up with the relentless march of technology. That's what Tellus App, Inc., a proptech company from Silicon Valley, is doing with its latest announcement to offer passkey sign-ins for its savings app across iOS, Android, and the web. In...

China's Health-Driven Poverty Approach Offers Global Lessons

China's Health Strategy in Poverty Reduction Here's a story that's got global implications tucked into its every corner: China, a country that's been trying to mesh healthcare with poverty reduction, has caught the eye of international observers. This insight was splashed across the latest Lancet Commission report, showcased at Tsinghua University on October 29. It seems...

WareSpace Expands in U.S. with Key Site Acquisitions

WareSpace's National Growth Strategy: A New Expansion Chapter They say everything's bigger in Texas, but WareSpace is showing that smaller can be mighty impactful too. With its shrewd acquisition of sites in Houston's Inner Loop and Fremont's Warm Springs corridor, WareSpace is playing it smart, appeasing that roaring demand for tiny but mighty warehouse spaces across...

XPLR Infrastructure Posts Solid Q3 Results, Eyes Growth

Third Quarter Results: Crunching the Numbers Every season brings new tidbits, and when XPLR Infrastructure, LP (NYSE: XIFR) dropped their third-quarter 2026 results, you bet I was ready with my magnifying glass. November 3rd was the day to circle on your calendars, as the folks over at Juno Beach sure had something to say. They’ve plastered the details across their...

Elanco Heads to UBS Global Healthcare—What Matters

Elanco's Strategy Under the Spotlight at UBS Confab Right off the bat, let's chew over why Elanco’s trip to the UBS Global Healthcare Conference ain’t just another checkbox on a corporate to-do list. It’s where the nitty-gritty of their strategy reveals itself, as Bob VanHimbergen and Bobby Modi step into the spotlight on November 9. While not everyone's shouting...

Stephanie Knepp Joins Exceptional Women Alliance

A New Chapter for a Seasoned Leader When a high flyer like Stephanie Knepp steps into a new arena, you know folks are going to sit up and pay attention. This time, she's making waves by joining the Exceptional Women Alliance (EWA), a heavy-hitting community of women leaders. With her extensive background in scaling businesses and empowering leaders, she's bound to bring...

2027 Shanghai Boat Show: 30 Years of Nautical Ambition

The 2027 Shanghai Boat Show: A Decades-Spanning Legacy You ever catch the wave just right, feeling that rush when the tide’s in your favor? That’s the buzz around the 2027 China (Shanghai) International Boat Show—better known as CIBS—celebrating its 30th anniversary. In this boat show shindig, we're looking at a whole host of innovations that could power up this...